Search results

Page results

• UCLH creating a toolkit to make more clinical trials open to young people

  A new research project spearheaded by the CCTU at UCLH is trying to make more places on clinical trials available to young cancer patients aged between 16 and 24 years.

• Professor Ed Wild contributes to new memoir by Charlotte Raven about her experience with Huntington’s disease

  Professor Ed Wild, NHNN consultant neurologist and associate director of UCL Huntington’s Disease Centre has contributed an afterword to a new memoir by journalist Charlotte Raven, called Patient 1, Forgetting and Finding Myself.

• Wearable tech, AI and clinical teams combine to change the face of clinical trial monitoring

  A multi-disciplinary team involving UCLH and UCL has developed a way to monitor the progression of movement disorders using motion capture technology and AI.

• Ward T16 North - Haematology

  T16 North is a specialist adult haematology inpatient ward dedicated to providing high-quality care for patients with a wide range of blood disorders.

• Patient story - Sam Ahern

  When Sam Ahern was born 24 years ago, she was the smallest baby our neonatal unit had ever looked after. Now an accomplished musician and fine art student, she has gone back to meet the team that helped her win her fight for life.

• In focus: cancer research using proton beam therapy

  More than 400 patients at UCLH have so far benefited from an exciting new cancer treatment called proton beam therapy (PBT) – which uses high-energy beams of protons, rather than X-rays, to deliver a dose of radiotherapy.

• COVID-19 NHS vaccination centre to reopen at Islington Business Design Centre

  UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.

• UCLH haematology team wins award

  Charity Myeloma UK awards UCLH haematology team their Clinical Service Excellence Programme (CSEP) award in recognition of their outstanding care and unflagging dedication to patients living myeloma, an incurable blood cancer.

• Immunomodulatory drug for COVID-19 trialled at UCLH

  UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).

• First UK proton beam therapy trial for breast cancer launches at UCLH

  The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched at UCLH.